# Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.

> **NCT07213076** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 350 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07213076
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2025-07-04
- **Primary completion:** 2025-11-10
- **Final completion:** 2025-11-10
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07213076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07213076, "Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT07213076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*